Editas Medicine (Nasdaq: EDIT) cuts 2025 loss and pushes EDIT-401 toward trials
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Editas Medicine reported sharply improved 2025 results while pivoting to its in vivo gene-editing program EDIT-401. Full-year net loss narrowed to
Collaboration and other R&D revenue grew to
Lead candidate EDIT-401 reduced mean LDL cholesterol by more than
Positive
- Substantial loss reduction and expense cuts: 2025 net loss narrowed to
$160.1M from$237.1M , driven by a$109.2M decrease in R&D and a$22.1M decrease in G&A as the company exited its former reni-cel program. - Extended cash runway and focused pipeline: With
$146.6M in cash and marketable securities and projected runway into the third quarter of2027 , Editas has time to advance EDIT-401 through IND/CTA submission, first-in-human HeFH trials, and early proof-of-concept milestones.
Negative
- High restructuring and impairment charges: Restructuring charges rose to
$60.7M in 2025 from$12.2M , reflecting costs tied to discontinuing the reni-cel program and associated workforce reduction, contributing materially to the year’s operating loss. - Reduced cash and equity base: Cash, cash equivalents, and marketable securities declined to
$146.6M from$269.9M year over year, while total stockholders’ equity fell to$27.3M from$134.3M , signaling a leaner balance sheet as the company invests in its in vivo strategy.
Insights
Editas narrows losses, extends cash runway, and centers growth on EDIT-401.
Editas Medicine significantly reduced its 2025 net loss to
Cash and marketable securities of
Execution now hinges on moving EDIT-401 into first-in-human HeFH testing in 2026 and generating early proof-of-concept data by year-end
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________________________________
FORM 8-K
_________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 9, 2026
_________________________________________________________________________________________
(Exact Name of Registrant as Specified in its Charter)
_________________________________________________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: (617 ) 401-9000
(Former Name or Former Address, if Changed Since Last Report)
__________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On March 9, 2026 , Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter and year ended December 31, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press release issued by the Company on March 9, 2026* | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
*This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EDITAS MEDICINE, INC. | ||||||||
Date: | By: | /s/ Amy Parison | ||||||
| Amy Parison | ||||||||
| Chief Financial Officer | ||||||||
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026
Preparing to initiate Company’s first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026
Strong cash position with cash runway into the third quarter of 2027
CAMBRIDGE, Mass., March 9, 2026 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates.
“We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in in vivo gene editing,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We continue to advance our lead in vivo development candidate, EDIT-401, an experimental, potential best-in-class, one-time therapy, which demonstrated significantly reduced mean LDL cholesterol levels of over 90 percent in preclinical studies. With cash runway into the third quarter of 2027, we are in a strong position to drive EDIT-401 toward upcoming milestones and look forward to submitting an IND/CTA by mid-2026 and initiating our first-in-human trial of EDIT-401 in patients living with heterozygous familial hypercholesterolemia (HeFH) later this year.”
Recent Achievements and Upcoming Milestones
•Editas continues to advance its lead in vivo development candidate, EDIT-401, which has demonstrated the potential to reduce mean LDL cholesterol levels by more than 90 percent in non-human primates, and will present additional preclinical data by mid-2026.
•The Company remains on track to submit an IND/CTA for EDIT-401 by mid-2026.
•Editas is preparing to initiate a first-in-human clinical trial in patients with HeFH later this year, and the Company is on track to achieve early human proof-of-concept data by the end of 2026.
•Editas plans to complete enrolling the dose-finding portion of the first-in-human clinical trial with topline data results available in 2027.
Upcoming Events
Editas Medicine plans to participate in the following investor event:
•Barclays 28th Annual Global Healthcare Conference
Format: Fireside Chat
Date: March 12, 2026
Time: 8:30 a.m. ET
Miami Beach, FL
To access a live webcast of the investor presentation, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.
Fourth Quarter and Full Year 2025 Financial Results
Cash and cash equivalents as of December 31, 2025, were $146.6 million compared to $269.9 million as of December 31, 2024. The Company expects that the existing cash and cash equivalents will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2027.
Fourth Quarter 2025
•For the three months ended December 31, 2025, net loss attributable to common stockholders was $5.6 million, or $0.06 per share, compared to net loss of $45.4 million, or $0.55 per share, for the same period in 2024.
•Collaboration and other research and development revenues decreased to $24.7 million for the three months ended December 31, 2025, compared to $30.6 million for the same period in 2024. The decrease is primarily attributable to the recognition of revenue related to milestones achieved under the Company’s collaboration agreement with BMS in the fourth quarter of 2024.
•Research and development expenses decreased by $21.2 million to $27.4 million for the three months ended December 31, 2025, compared to $48.6 million for the same period in 2024. The decrease is primarily related to reduced clinical and manufacturing costs related to discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024, partially offset by costs attributable to in vivo research and discovery.
•General and administrative expenses decreased by $5.0 million to $11.4 million for the three months ended December 31, 2025, compared to $16.4 million for the same period in 2024. The decrease is primarily attributable to a reduction in employee-related expenses related to reduced headcount associated with the reduction in workforce, as well as reduced professional services in connection with the discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024.
•Restructuring and impairment charges decreased by $18.5 million to a $6.3 million benefit for the three months ended December 31, 2025, compared to $12.2 million for the same period in 2024. The decrease is primarily attributable to favorable adjustments to prior estimated costs for contracts associated with the discontinuation of the clinical development of the Company’s reni-cel program upon finalization of contract costs.
Full Year 2025
•For the full year 2025, net loss attributable to common stockholders was $160.1 million, or $1.80 per share, compared to net loss of $237.1 million, or $2.88 per share, for the same period in 2024.
•Collaboration and other research and development revenues increased to $40.5 million for 2025, compared to $32.3 million for the same period in 2024. The increase was attributable to recognition of the remaining deferred revenue upon the conclusion of a collaboration agreement with a strategic partner, as well as recognition of revenue related to a milestone achieved in 2025 under our collaboration with BMS.
•Research and development expenses decreased by $109.2 million to $90.0 million for 2025, compared to $199.2 million for the same period in 2024. The decrease was primarily attributable to reduced clinical and manufacturing costs due to the discontinuation of the Company’s former reni-cel program, partially offset by costs attributable to in vivo research and discovery.
•General and administrative expenses decreased by $22.1 million to $49.9 million for 2025, compared to $72.0 million for the same period in 2024. The decrease was primarily related to reduced headcount associated with the workforce reduction and reduced professional services related to the discontinuation of the Company’s former reni-cel program.
•Restructuring and impairment charges increased by $48.4 million to $60.7 million for 2025, compared to $12.2 million for the same period in 2024. The increase was attributable actions associated with the discontinuation of the Company’s former reni-cel program and the associated workforce reduction.
About Heterozygous Familial Hypercholesterolemia (HeFH)
Heterozygous Familial Hypercholesterolemia (HeFH) is an inherited genetic disorder that leads to significantly elevated LDL‑cholesterol levels from an early age. Individuals with HeFH are at high risk of heart disease, heart attack, or stroke if the condition is not identified and treated early. An estimated 1.2 million people in the United States are living with HeFH, though many remain undiagnosed. Elevated LDL-C, also known as hyperlipidemia, is a highly prevalent disease affecting over 70 million patients in the United States alone. Substantial unmet need exists across multiple at-risk segments of patients with hyperlipidemia, including the HeFH population.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company’s preclinical studies and planned clinical trials, including the Company’s expectation to achieve early human proof-of-concept data for EDIT-401 by year-end 2026 and complete enrolling the dose-finding portion of the EDIT-401 clinical trial with topline data results available in 2027; the timing for the Company’s receipt and presentation of data from its preclinical studies, including presenting additional preclinical data for EDIT-401 by mid-2026; the potential of, and expectations for, EDIT-401 and the Company’s other future in vivo product candidates; the timing or likelihood of regulatory submissions and approvals, including the timing of submission of an IND/CTA for EDIT-401 by mid-2026; and the Company’s expectations regarding its cash runway and the milestones that can be achieved with that cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated; and that the Company will not be able to raise funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
EDITAS MEDICINE, INC.
Consolidated Statement of Operations
(amounts in thousands, except share and per share data)
(Unaudited)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Collaboration and other research and development revenues | $ | 24,741 | $ | 30,604 | $ | 40,520 | $ | 32,314 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 27,404 | 48,611 | 89,953 | 199,247 | |||||||||||||||||||
| General and administrative | 11,353 | 16,354 | 49,903 | 71,987 | |||||||||||||||||||
| Restructuring charges | (6,261) | 12,232 | 60,674 | 12,232 | |||||||||||||||||||
| Total operating expenses | 32,496 | 77,197 | 200,530 | 283,466 | |||||||||||||||||||
| Operating loss | (7,755) | (46,593) | (160,010) | (251,152) | |||||||||||||||||||
| Other income (expense), net: | |||||||||||||||||||||||
| Interest expense related to sale of future revenues | 464 | (2,190) | (6,171) | (2,190) | |||||||||||||||||||
| Interest income, net | 1,676 | 3,391 | 8,310 | 16,252 | |||||||||||||||||||
| Other expense, net | (5) | (3) | (2,189) | (3) | |||||||||||||||||||
| Total other income (expense), net | 2,135 | 1,198 | (50) | 14,059 | |||||||||||||||||||
| Net loss | $ | (5,620) | $ | (45,395) | $ | (160,060) | $ | (237,093) | |||||||||||||||
| Net loss per share, basic and diluted | $ | (0.06) | $ | (0.55) | $ | (1.80) | $ | (2.88) | |||||||||||||||
| Weighted-average common shares outstanding, basic and diluted | 97,255,149 | 82,613,831 | 88,745,908 | 82,338,220 | |||||||||||||||||||
EDITAS MEDICINE, INC.
Selected Consolidated Balance Sheet Items
(amounts in thousands)
(Unaudited)
| December 31, | December 31, | ||||||||||
| 2025 | 2024 | ||||||||||
| Cash, cash equivalents, and marketable securities | $ | 146,645 | $ | 269,913 | |||||||
| Working capital | 117,649 | 212,090 | |||||||||
| Total assets | 186,534 | 341,589 | |||||||||
| Deferred revenue, net of current portion | 44,509 | 54,204 | |||||||||
| Total stockholders' equity | 27,288 | 134,274 | |||||||||
###
Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com
FAQ
How did Editas Medicine (EDIT) perform financially in full-year 2025?
Editas Medicine cut its 2025 net loss to $160.1 million, or $1.80 per share, from $237.1 million, or $2.88 per share, in 2024. The improvement mainly reflects lower research and development and general and administrative expenses after discontinuing its former reni-cel program.
What is Editas Medicine’s cash position and runway after 2025?
Editas ended 2025 with $146.6 million in cash, cash equivalents, and marketable securities. The company expects this to fund operating and capital needs into the third quarter of 2027, supporting advancement of its in vivo gene-editing pipeline, including key milestones for lead candidate EDIT-401.
What progress did Editas Medicine report on its EDIT-401 program?
EDIT-401 showed over 90% mean LDL-cholesterol reduction in non-human primates. Editas plans an IND/CTA submission by mid-2026, initiation of a first-in-human HeFH trial later 2026, and aims for early human proof-of-concept data by year-end 2026, with topline dose-finding data expected in 2027.
How did Editas Medicine’s revenues change in 2025?
Collaboration and other R&D revenues increased to $40.5 million in 2025 from $32.3 million in 2024. This growth was driven by recognition of remaining deferred revenue from a concluded collaboration and a milestone payment under its collaboration with BMS, partially offsetting lower quarterly collaboration revenue.
What restructuring actions affected Editas Medicine’s 2025 results?
In 2025, Editas recorded $60.7 million in restructuring and impairment charges, up from $12.2 million in 2024. These charges stem from discontinuing the former reni-cel program and related workforce reductions, reshaping the cost structure toward in vivo research and development, including EDIT-401.
How did Editas Medicine’s quarterly performance change in Q4 2025?
For Q4 2025, net loss attributable to common stockholders was $5.6 million, or $0.06 per share, versus $45.4 million, or $0.55 per share, a year earlier. Lower R&D and G&A expenses and a $6.3 million restructuring benefit drove the substantial quarterly improvement.
Filing Exhibits & Attachments
5 documentsPress Releases
Editas Medicine Inc
NASDAQ:EDIT
EDIT Rankings
EDIT Latest News
EDIT Latest SEC Filings
Mar 9, 2026
[10-K] Editas Medicine, Inc. Files Annual Report
Feb 27, 2026
[144] Editas Medicine, Inc. SEC Filing
EDIT Stock Data
195.24M
97.11M
Biotechnology
Biological Products, (no Diagnostic Substances)
United States
CAMBRIDGE